Results 201 to 210 of about 4,926,176 (337)

Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study [PDF]

, 2015
Aaron S. Kesselheim, Bo Wang, Jessica M. Franklin, Jonathan J. Darrow   +3 more
openalex   +1 more source

ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials

Annals of Internal Medicine, 2016
Lisa M. Schwartz, S. Woloshin, Eugene Zheng, Tony Tse, D. Zarin   +4 more
semanticscholar   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Critical insights into the evolving drug-approval process in China. [PDF]

Cancer
Nikanjam M, Kurzrock R.
europepmc   +1 more source

An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC). [PDF]

BMC Cancer, 2022
Sharp J, Prasad V.
europepmc   +1 more source

Accelerated orphan drug approval: surrogate endpoints

, 2022
Candida Fratazzi, Jixiao Niu
openalex   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Editorial: Streamlining drug approvals: addressing policy challenges in genitourinary oncology

Frontiers in Immunology
Guglielmo Mantica, Robert Hsu, Renate Pichler, David J. Benjamin   +3 more
doaj   +1 more source

Machine Learning with Statistical Imputation for Predicting Drug Approval

Harvard Data Science Review, 2021
Andrew W. Lo, Kien Wei Siah, Chi Heem Wong   +2 more
doaj   +1 more source

Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non-Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns. [PDF]

Clin Cancer Res
Koban MU, Hartmann M, Amexis G, Franco P, Huggins L, Shah I, Karachaliou N.   +6 more
europepmc   +1 more source